Endevica Bio has dosed the first patient in a Phase 2 trial evaluating TCMCB07 (B07) to prevent weight loss and cachexia in stage 4 metastatic colorectal cancer patients undergoing chemotherapy.
Endevica Bio has received FDA authorization to begin a Phase 2 clinical trial of TCMCB07 (B07), a peptide designed to prevent weight loss in stage 4 metastatic colorectal cancer patients undergoing chemotherapy.
Cancer cachexia, a devastating wasting syndrome affecting up to 40% of cancer patients, is gaining recognition as a critical therapeutic target beyond traditional tumor-focused treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.